Compared with placebo, DPP-4 inhibitors showed generally neutral associations across respiratory outcomes, with non-significant trends toward reduced risks of pneumonia, pulmonary embolism, respiratory failure, and bronchitis. Here, DPP4 is linked to pneumonia.